The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
Open accessAbstract
Summary Background Figitumumab is a fully human IgG2 monoclonal antibody targeting the insulin-like growth-factor-1 receptor (IGF-1R). Preclinical data suggest a dependence on insulin-like growth-factor signalling for sarcoma subtypes, including Ewing’s sarcoma, and early reports show antitumour activity of IGF-1R-targeting drugs in these diseases. Methods Between January, 2006, and August, 2008, patients with refractory, advanced sarcomas received figitumumab (20 mg/kg) in two single-stage expansion cohorts within a solid-tumour phase 1 trial. The first cohort (n=15) included patients with multiple sarcoma subtypes, age 18 years or older, and the second cohort (n=14) consisted of patients with refractory Ewing’s sarcoma, age 9 years or older. The primary endpoint was to assess the safety and tolerability of figitumumab. Secondary endpoints included pharmacokinetic profiling and preliminary antitumour activity (best response by Response Evaluation Criteria in Solid Tumours [RECIST]) in evaluable patients who received at least one dose of medication. This study is registered with ClinicalTrials.gov, number NCT00474760. Findings 29 patients, 16 of whom had Ewing’s sarcoma, were enrolled and received a total of 177 cycles of treatment (median 2, mean 6·1, range 1–24). Grade 3 deep venous thrombosis, grade 3 back pain, and grade 3 vomiting were each noted once in individual patients; one patient had grade 3 increases in aspartate aminotransferase and gammaglutamyltransferase concentrations. This patient also had grade 4 increases in alanine aminotransferase concentrations. The only other grade 4 adverse event was raised concentrations of uric acid, noted in one patient. Pharmacokinetics were comparable between patients with sarcoma and those with other solid tumours. 28 patients were assessed for response; two patients, both with Ewing’s sarcoma, had objective responses (one complete response and one partial response) and eight patients had disease stabilisation (six with Ewing’s sarcoma, one with synovial sarcoma, and one with fibrosarcoma) lasting 4 months or longer. Interpretation Figitumumab is well tolerated and has antitumour activity in Ewing’s sarcoma, warranting further investigation in this disease. Funding Pfizer Global Research and Development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Karp, D. D., Paz-Ares, L. G., Novello, S., Haluska, P., Garland, L., Cardenal, F., Blakely, L. J., Eisenberg, P. D., Langer, C. J., Blumenschein, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9331 · Cited by 260
Self-citationRetractedEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., & Pollak, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10384-1 · Cited by 1,823
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0001 · Cited by 1,005
Massagué, J., & Czech, M. P. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34631-3 · Cited by 711
Short-Term Metabolic Effects of Recombinant Human Insulin-like Growth Factor I in Healthy Adults
Guler, H.-P., Zapf, J., & Froesch, E. R. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170303 · Cited by 554
Mechanisms of sarcoma development
Helman, L. J., & Meltzer, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1168 · Cited by 460
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Van Glabbeke, M., Verweij, J., Judson, I., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 424
Self-citationCohen, B. D., Baker, D. A., Soderstrom, C., Tkalcevic, G., Rossi, A. M., Miller, P. E., Tengowski, M. W., Wang, F., Gualberto, A., Beebe, J. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1070 · Cited by 365
Self-citation
Cited by
The insulin and insulin-like growth factor receptor family in neoplasia: an update
Pollak, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3215 · Cited by 1,116
Balamuth, N. J., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 686
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Maki, R. G., D'Adamo, D. R., Keohan, M. L., Saulle, M., Schuetze, S. M., Undevia, S. D., Livingston, M. B., Cooney, M. M., Hensley, M. L., Mita, M. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4495 · Cited by 569
Self-citationThe Type 1 Insulin-Like Growth Factor Receptor Pathway
Chitnis, M. M., Yuen, J. S. P., Protheroe, A. S., Pollak, M., & Macaulay, V. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4879 · Cited by 445
Advances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3087 · Cited by 427
Metadata
- Authors
- Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., Batzel, G. N., Yin, D., Pritchard-Jones, K., Judson, I., Worden, F. P., Gualberto, A., Scurr, M., de Bono, J. S., & Haluska, P.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 11
- Issue
- 2
- Pages
- 129-135
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2152274262
- Cited by
- 340
- References
- 32
- FWCI
- 32.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(09)70354-7
- The paper
- Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., Batzel, G. N., Yin, D., Pritchard-Jones, K., Judson, I., Worden, F. P., Gualberto, A., Scurr, M., de Bono, J. S., & Haluska, P. (2010). Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(09)70354-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.